Leabaneng Tawe1,2, Surbhi Grover2,3, Nicola Zetola2, Erle S Robertson4, Simani Gaseitsiwe5,6, Sikhulile Moyo5,6, Ishmael Kasvosve1, Giacomo M Paganotti2,7,8, Mohan Narasimhamurthy9. 1. Department of Medical Laboratory Sciences, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana. 2. Botswana-University of Pennsylvania Partnership, Gaborone, Botswana. 3. Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. 4. Department of Otorhinolaryngology-Head and Neck Surgery, and the Tumor Virology Program, Abramson Comprehensive Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. 5. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. 6. Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, United States. 7. Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States. 8. Department of Biomedical Sciences, Faculty of Medicine, University of Botswana, Gaborone, Botswana. 9. Department of Pathology, Faculty of Medicine, University of Botswana, Gaborone, Botswana.
Abstract
Background: Epidemics of human immunodeficiency virus (HIV) and cervical cancer are interconnected. DNA hypermethylation of host genes' promoter in cervical lesions has also been recognized as a contributor to cervical cancer progression. Methods: For this purpose we analyzed promoter methylation of four tumor suppressor genes (RARB, CADM1, DAPK1 and PAX1) and explored their possible association with cervical cancer in Botswana among women of known HIV status. Overall, 228 cervical specimens (128 cervical cancers and 100 non-cancer subjects) were used. Yates-corrected chi-square test and Fisher's exact test were used to explore the association of promoter methylation for each host gene and cancer status. Subsequently, a logistic regression analysis was performed to find which factors, HIV status, high risk-HPV genotypes, patient's age and promoter methylation, were associated with the following dependent variables: cancer status, cervical cancer stage and promoter methylation rate. Results: In patients with cervical cancer the rate of promoter methylation observed was greater than 64% in all the genes studied. Analysis also showed a higher risk of cervical cancer according to the increased number of methylated promoter genes (OR = 6.20; 95% CI: 3.66-10.51; P < 0.001). RARB methylation showed the strongest association with cervical cancer compared to other genes (OR = 15.25; 95% CI: 6.06-40.0; P < 0.001). Cervical cancer and promoter methylation of RARB and DAPK1 genes were associated with increasing age (OR = 1.12; 95% CI: 1.01-1.26; P = 0.037 and OR = 1.05; 95% CI: 1.00-1.10; P = 0.040). The presence of epigenetic changes at those genes appeared to be independent of HIV status among subjects with cervical cancer. Moreover, we found that cervical cancer stage was influenced by RARB (χ2= 7.32; P = 0.002) and CADM1 (χ2=12.68; P = 0.013) hypermethylation, and HIV status (χ2= 19.93; P = 0.001). Conclusion: This study confirms the association between invasive cervical cancer and promoter gene methylation of tumor suppressing genes at the site of cancer. HIV infection did not show any association to methylation changes in this group of cervical cancer patients from Botswana. Further studies are needed to better understand the role of HIV in methylation of host genes among cancer subjects leading to cervical cancer progression.
Background: Epidemics of humanimmunodeficiency virus (HIV) and cervical cancer are interconnected. DNA hypermethylation of host genes' promoter in cervical lesions has also been recognized as a contributor to cervical cancer progression. Methods: For this purpose we analyzed promoter methylation of four tumor suppressor genes (RARB, CADM1, DAPK1 and PAX1) and explored their possible association with cervical cancer in Botswana among women of known HIV status. Overall, 228 cervical specimens (128 cervical cancers and 100 non-cancer subjects) were used. Yates-corrected chi-square test and Fisher's exact test were used to explore the association of promoter methylation for each host gene and cancer status. Subsequently, a logistic regression analysis was performed to find which factors, HIV status, high risk-HPV genotypes, patient's age and promoter methylation, were associated with the following dependent variables: cancer status, cervical cancer stage and promoter methylation rate. Results: In patients with cervical cancer the rate of promoter methylation observed was greater than 64% in all the genes studied. Analysis also showed a higher risk of cervical cancer according to the increased number of methylated promoter genes (OR = 6.20; 95% CI: 3.66-10.51; P < 0.001). RARB methylation showed the strongest association with cervical cancer compared to other genes (OR = 15.25; 95% CI: 6.06-40.0; P < 0.001). Cervical cancer and promoter methylation of RARB and DAPK1 genes were associated with increasing age (OR = 1.12; 95% CI: 1.01-1.26; P = 0.037 and OR = 1.05; 95% CI: 1.00-1.10; P = 0.040). The presence of epigenetic changes at those genes appeared to be independent of HIV status among subjects with cervical cancer. Moreover, we found that cervical cancer stage was influenced by RARB (χ2= 7.32; P = 0.002) and CADM1 (χ2=12.68; P = 0.013) hypermethylation, and HIV status (χ2= 19.93; P = 0.001). Conclusion: This study confirms the association between invasive cervical cancer and promoter gene methylation of tumor suppressing genes at the site of cancer. HIV infection did not show any association to methylation changes in this group of cervical cancerpatients from Botswana. Further studies are needed to better understand the role of HIV in methylation of host genes among cancer subjects leading to cervical cancer progression.
Authors: Eunice C Chan; Shui Y Lam; Kenneth W Tsang; Bing Lam; James C M Ho; Kin H Fu; Wah K Lam; Yok L Kwong Journal: Clin Cancer Res Date: 2002-12 Impact factor: 12.531
Authors: M Widschwendter; J Berger; M Hermann; H M Müller; A Amberger; M Zeschnigk; A Widschwendter; B Abendstein; A G Zeimet; G Daxenbichler; C Marth Journal: J Natl Cancer Inst Date: 2000-05-17 Impact factor: 13.506
Authors: J A Mikovits; H A Young; P Vertino; J P Issa; P M Pitha; S Turcoski-Corrales; D D Taub; C L Petrow; S B Baylin; F W Ruscetti Journal: Mol Cell Biol Date: 1998-09 Impact factor: 4.272
Authors: Renske D M Steenbergen; Debbie Kramer; Boudewijn J M Braakhuis; Peter L Stern; René H M Verheijen; Chris J L M Meijer; Peter J F Snijders Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Gaone Retshabile; Busisiwe C Mlotshwa; Lesedi Williams; Savannah Mwesigwa; Gerald Mboowa; Zhuoyi Huang; Navin Rustagi; Shanker Swaminathan; Eric Katagirya; Samuel Kyobe; Misaki Wayengera; Grace P Kisitu; David P Kateete; Eddie M Wampande; Koketso Maplanka; Ishmael Kasvosve; Edward D Pettitt; Mogomotsi Matshaba; Betty Nsangi; Marape Marape; Masego Tsimako-Johnstone; Chester W Brown; Fuli Yu; Adeodata Kekitiinwa; Moses Joloba; Sununguko W Mpoloka; Graeme Mardon; Gabriel Anabwani; Neil A Hanchard Journal: Am J Hum Genet Date: 2018-04-26 Impact factor: 11.025
Authors: Ananyo Choudhury; Shaun Aron; Laura R Botigué; Dhriti Sengupta; Gerrit Botha; Taoufik Bensellak; Gordon Wells; Judit Kumuthini; Daniel Shriner; Yasmina J Fakim; Anisah W Ghoorah; Eileen Dareng; Trust Odia; Oluwadamilare Falola; Ezekiel Adebiyi; Scott Hazelhurst; Gaston Mazandu; Oscar A Nyangiri; Mamana Mbiyavanga; Alia Benkahla; Samar K Kassim; Nicola Mulder; Sally N Adebamowo; Emile R Chimusa; Donna Muzny; Ginger Metcalf; Richard A Gibbs; Charles Rotimi; Michèle Ramsay; Adebowale A Adeyemo; Zané Lombard; Neil A Hanchard Journal: Nature Date: 2020-10-28 Impact factor: 69.504